NCT03929029 — Dana-Farber Cancer Institute neoantigen vaccine trial
Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma
Registry record
| Registry ID | NCT03929029 ↗ |
|---|---|
| Lead sponsor | Dana-Farber Cancer Institute |
| Collaborators | National Cancer Institute (NCI) |
| Phase | Phase 1 |
| Status | Active Not Recruiting |
| Indication | Cutaneous Melanoma |
| Enrollment | 11 participants (target) |
| Start date | 2020-11-11 |
| Primary completion | 2022-12-27 |
| Last registry update | 5 Jan 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT03929029), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT03929029?
NCT03929029 (Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma) is registered on ClinicalTrials.gov as Phase 1, sponsored by Dana-Farber Cancer Institute.
Is NCT03929029 recruiting?
As of the 2026-01-05 registry update, NCT03929029 is listed as "Active Not Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT03929029?
The lead sponsor is Dana-Farber Cancer Institute. Collaborators: National Cancer Institute (NCI).
What condition does NCT03929029 study?
The registered condition is Cutaneous Melanoma. Primary completion is listed as 2022-12-27.
Are results available for NCT03929029?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT03929029.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.